News for Turning Point Therapeutics, Inc. (TPTX)

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced that the 2024 National Reimbursement Drug List (NRDL) released by China's National Healthcare Securi

Zai Lab Announces the Inclusion of AUGTYRO ® (repotrectinib) for ROS1+ NSCLC and Other Updates in China's National Reimbursement Drug List

August 12, 2024 (Investorideas.com Newswire) Investorideas.com, a go-to investing platform covering biotech and medical technology issues a snapshot on recent n...

Garry A. Nicholson, an experienced executive with regulatory and commercial expertise, joins the Board of Directors Timothy Barberich retires as Chair; Stephen Biggar, M.D., Ph.D. assumes the role...

Zai Lab Announces Approval of AUGTYRO™ (repotrectinib) for Patients with ROS1-positive NSCLC by China's NMPA

BELOIT, Wis. — NorthStar Medical Technologies, LLC, parent company of NorthStar Medical Radioisotopes, LLC, a global innovator in development, production and…

Phase 1/2 TRIDENT-1 study data demonstrate repotrectinib’s clinically meaningful response rates and durable clinical activity in patients with ROS1-positive non-small cell lung cancer Data show...

The advancements that have been made in computational biology have made the data analytics and analysis phases of gene sequencing much more...

"Pioneering Biotech Investment: A Patient-Centric Approach" - Explore innovative ways in which biotech investments are reshaping the industry with a focus on patient well-being. Learn how this visionary approach is driving progress in healthcare and investment, all in this insightful article.

Candidate precision medicine has shown encouraging clinical activity for both ROS1-positive NSCLC and NTRK fusion-positive advanced solid tumorsSHANGHAI, China and CAMBRIDGE, Mass., Aug. 30, 2023 ...

/PRNewswire/ -- DelveInsight's 'Gastric Cancer Pipeline Insight – 2022' report provides comprehensive global coverage of available, marketed, and pipeline...

CRANBURY, N.J., Nov. 04, 2022 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and...

For RGA Investment Advisors, the third quarter saw a continuation of the ugly trend from the first half of the year. Click here to read the full fund letter.

I tried to cross-tally the list of funds and companies banned by the Texas Comptroller with the publicly available holdings of Texan state pension funds. I found little overlap. I wonder whether the banned list was even meant to bite.

BALA CYNWYD, Pa., June 06, 2022 (GLOBE NEWSWIRE) -- Brodsky & Smith reminds investors of the following investigations. If you own shares and wish to...

Gainers Turning Point Therapeutics, Inc. (NASDAQ: TPTX) shares climbed 118.4% to close at $74.59 on Friday after Bristol Myers Squibb announced it will acquire Turning Point Therapeutics for $76 per share.

Read Investment Analysts’ Updated EPS Estimates for June 3rd (ACC, ACCO, ADSE, ADXN, AER, AFLYY, ALLG, ALSMY, AMRX, APS) at ETF Daily News

Read Equities Research Analysts’ Downgrades for June 3rd (ANSLY, AON, BLRX, BMY, CNTA, CNX, ENTA, FGBI, GHL, HSTM) at ETF Daily News

Read Stock Analysts’ Price Target Changes for May 11th (ABCL, ABST, AHCO, AIP, AIR, ALEC, ALGM, ALO, ALTG, ALV) at ETF Daily News